

FOIA MARKER

**This is not a textual record. This is used as an
administrative marker by the William J. Clinton
Presidential Library Staff.**

Collection/Record Group:	Clinton Presidential Records
Subgroup/Office of Origin:	National AIDS Policy Office
Series/Staff Member:	Patsy Fleming
Subseries:	National AIDS Strategy

OA/ID Number:	10183
FolderID:	

Folder Title:
[Patsy Fleming Correspondence April 1997]

Stack:	Row:	Section:	Shelf:	Position:
S	66	5	10	3

April

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: G3617

Date Rcvd: 03-25-97

From: Lori Block
Resume

Staff Action:

Reviewed By Eric:  Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

Donet / Comm

To Support Staff: _____

Date of Response: 4-3-97

THE WHITE HOUSE

WASHINGTON

APR 3 1997


Ms. Lori Block
8 Charles Plaza, #405
Baltimore, MD 21201

Dear Ms. Block:

Thank you for your letter to Patricia Fleming indicating your interest in working in the Office of National AIDS Policy. Ms. Fleming is no longer with this office. Your qualifications and experience are impressive and would be an asset to any office. Unfortunately, there are no openings at this time.

Knowledge of laws and policy development around AIDS issues are becoming ever more important, as evidenced by the mandatory testing and blinded survey issues. I encourage you to continue your involvement in your community's response to the AIDS epidemic.

Sincerely,

A handwritten signature in black ink, appearing to read "E. Goosby", with a stylized flourish at the end.

Eric P. Goosby, MD
Acting Director
National AIDS Policy Office

Lori Block
8 Charles Plaza #405
Baltimore, MD 21201

March 19, 1997

Patricia Fleming
National AIDS Policy Office
750 17th St., N.W. Suite 600
Washington, D.C. 20503

Dear Ms. Fleming:

I am a Master of Health Science candidate in Health Policy at the Johns Hopkins University School of Hygiene and Public Health. I will complete my coursework in May, and am seeking a health policy related position. I am interested in speaking with you about possible employment opportunities with the National AIDS Policy Office.

Prior to attending Johns Hopkins, I was a practicing attorney for eight years. I believe that my research, writing, and analytical skills would be a valuable asset in analyzing health policy.

My resume is included for your review. I appreciate your consideration and look forward to hearing from you.

Sincerely,

A handwritten signature in cursive script that reads "Lori Block".

Lori Block

Enclosure

Lori Block

8 Charles Plaza # 405 Baltimore, MD 21201

Phone 410/783-7858 Fax 410/614-9331 e-mail lblock@sph.jhu.edu

EDUCATION

The Johns Hopkins University School of Hygiene and Public Health

Baltimore, Maryland

MASTER OF HEALTH SCIENCE IN HEALTH POLICY, EXPECTED MAY 1998

The University of Tulsa College of Law

Tulsa, Oklahoma

JURIS DOCTORATE, MAY 1988

Oklahoma State University

Stillwater, Oklahoma

BACHELOR OF ARTS WITH HONORS IN POLITICAL SCIENCE, MAY 1985

ACTIVITIES

Young Democrats, OSU Chapter President

OSU Political Science Newsletter, Editor

Phi Delta Phi, legal fraternity

Phi Kappa Phi, scholastic fraternity

EXPERIENCE

AmeriCorps - Youth and HIV Project

PLANNED PARENTHOOD

October 1994 - August 1996

TULSA, OKLAHOMA

- Served on Executive Planning Committee for the First Regional Conference of HIV/AIDS and Women.
- Coordinated consortium of women-focused social service agencies to provide HIV/AIDS prevention education and HIV antibody testing for their clients.
- Developed HIV/AIDS related library at Planned Parenthood.
- Counseled and administered HIV Antibody tests to clients.
- Presented HIV/AIDS information programs to Planned Parenthood staff and to various community groups.
- Developed needs assessment for Ryan White Community Planning Group.

Municipal Judge

January 1992 - August 1996

KIEFER, OKLAHOMA AND MOUNDS, OKLAHOMA

- Presided over misdemeanor bench and jury trials.
- Conducted weekly traffic court.

Attorney at Law

April 1989 - August 1996

SAPULPA, OKLAHOMA

- Counseled municipal officials regarding contract, employment, and tort law.
- Drafted contracts, briefs, motions, and correspondence.

Intern

CREEK COUNTY DISTRICT ATTORNEY'S OFFICE

October 1988 - April 1989

SAPULPA, OKLAHOMA

- Assisted in preparation and trial of felony jury cases.
 - Drafted briefs, motions, interrogatories, and other documents.
-

PROFESSIONAL MEMBERSHIPS

- AMERICAN PUBLIC HEALTH ASSOCIATION
- AMERICAN BAR ASSOCIATION
- OKLAHOMA BAR ASSOCIATION

School of Hygiene and Public Health

Department of Health Policy and Management
624 N. Broadway
Baltimore MD 21205-1999

The MHS in Health Policy Program

The Master of Health Science (MHS) in Health Policy Program prepares students for positions as health policy analysts in federal agencies, the legislative arena, state and local governments, research organizations, advocacy and interest groups, and health service settings. It is a two-year program requiring one academic year of full-time coursework and a nine-month paid, supervised field placement.

The curriculum is designed to help students understand major health policy issues, including access to care for vulnerable populations, the organization, financing and delivery of health services, environmental and occupational health policy, health law and regulation, and the process by which public policy decisions are made. The curriculum is designed to teach students how to use and critique data and research results for health policy analysis. Students also receive training in basic biostatistics and epidemiological research methods. Elective courses may be selected from those offered by the Department of Health and Management or any department in the School of Public Health with the consent of the student's advisor.

Each student must satisfactorily complete the required course work and a minimum of 64 units prior to beginning the field placement. The field placement is an integral part of the MHS in Health Policy Program and is an activity in which the student, the field placement office, and the faculty share responsibility. The primary purpose of the field placement is to provide an opportunity for students to apply the theories and principles learned from their academic course work and to develop skills that are essential for functioning as an effective health policy analyst.

Organizations and agencies that provide field placements will be required to identify a "preceptor" who will serve as an academic and professional mentor to the student. The preceptor will be offered an opportunity for an Associate appointment with the Department of Health Policy and Management for the duration of the field placement. At the convenience of the preceptor, the Associate Director of the MHS in Health Policy Program will arrange for one or two site visits to evaluate the field placement experience from the point of view of both the preceptor and the student. In addition to the responsibilities assigned by the field placement office, students are required to submit periodic reports to the Program Director, their academic advisors, and their preceptors.

For additional information about the MHS in Health Policy Program please contact the program office at (410) 614-1535.

FILE COPY

Office of
National AIDS Policy

Correspondence Routing Slip

Tracking Number: G-3613

Date Rcvd: 3/24/97

From: Rod Hoff, SCD @ HHS

Staff Action:

Reviewed By Eric: UL Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

copy Deb V
Elaine Daniels

To Support Staff: _____

Date of Response: 3-28-97

n:\corresli



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

March 11, 1997

Dr. Eric Goosby
Acting Director
National AIDS Policy Office
750 17th St., NW
Washington, DC 20503

Dear Colleague,

An important question in HIV research is what role Nonoxynol-9 containing microbicides can play in HIV prevention. Field work has recently been completed on a Phase III study of the safety and efficacy of N-9 Film (Vaginal Contraceptive Film - Apothecus) for the prevention of heterosexual transmission of HIV transmission among female sex workers in Cameroon. The study was conducted by Ron Roddy and Dr. Leopold Zeking.

The investigators have agreed to release the preliminary findings from their study in a public meeting sponsored by NIAID. We believe that this approach will allow for an extensive presentation of the data and discussion of their implications. This meeting will take place at the Hyatt Regency Hotel in Bethesda, Maryland on April 9, 1997. The Hyatt Regency is located at One Bethesda Metro Center, Bethesda, Maryland, 20814 (Phone: 1-301-657-1234).

Please see the enclosed draft agenda for further details of the meeting. I encourage you to attend and share this letter with other colleagues interested in this research.

Best regards,

A handwritten signature in black ink, which appears to read "Rod Hoff", followed by the initials "(CH)" in parentheses.

Rod Hoff, ScD
Chief, Efficacy Trials Branch
DAIDS/NIAID/NIH

PROVISIONAL AGENDA
N-9 FILM TRIAL IN CAMEROON: RESULTS AND IMPLICATIONS
Efficacy Trials Branch, Division of AIDS
National Institute of Allergy and Infectious Diseases

DATE: April 9, 1997
PLACE: Haverford Room, Hyatt Regency Hotel, Bethesda, Maryland
CHAIRS: Sharilyn Stanley, MD (NIAID/OD), Ward Cates, MD, MPH (FHI)

- 8:00 Registration
- 8:30 Welcome - NIAID
- 8:45 Overview of N-9 Microbicides, Ward Cates, MD (Family Health International)
- 9:00 N-9 Film Trial: Methods and Results, Ron Roddy, PA (Family Health International)
- 10:00 Break
- 10:45 Critique of Study Methodology: Statistician TBA
- 11:00 General Discussion
- 12:00 Lunch
- 1:30 Round Table Discussion (up to 15 minutes each)
 - NIH
 - CDC
 - FDA
 - UNAIDS
 - Apothecus (N-9 Film Manufacturer)
 - State/Local Health Department
 - Community Perspective
- 3:00 Break
- 3:30 General Discussion
- 5:00 Adjourn

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

on calendar
April 9

Tracking Number: G3621

Date Rcvd: 03-27-97

From: Daniel Zingale
AIDS ACTION

Staff Action:

Reviewed By Eric: _____ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

OK - But on calendar
(if I'm not going to Geneva
or back by 9th)
see 3604

To Support Staff: _____

Date of Response: 4-9-97

n:\corresli Cancelled on Daniel Zingale's voice mail

C



March 20, 1997

Dr. Eric Goosby
Acting National AIDS Policy Coordinator
750 17th Street, NW Room 1060
Washington, DC 20503

Dear Dr. Goosby:

Thank you for accepting our invitation to attend the AIDS Action Foundation National Leadership Awards to be held Wednesday April 9. The evening will be a wonderful opportunity to recognize some of those who have shown outstanding leadership in the fight against AIDS. Your tickets will be held at the door.

Friends like you help AIDS Action in the fight for public policies that will expand access to care, housing and new drug treatments for those living with HIV and AIDS. Your support makes a real difference in the lives of people battling the daily challenges of HIV disease. On behalf of the AIDS Action board members and staff, thank you.

With warm regards,

A handwritten signature in black ink that reads "Daniel Zingale". The signature is written in a cursive, flowing style.

Daniel Zingale
Executive Director

1875
Connecticut Ave NW
Suite 700
Washington DC
20009
Fax 202 986 1345
Tel 202 986 1300

The Board of Directors of **AIDS Action Foundation**,

Daniel Zingale, Executive Director,

cordially invites you to honor the 1997

National Leadership Award Recipients

Vice President and Mrs. Al Gore, Jr.
PUBLIC SERVICE

Nancy-Ann Min
PUBLIC POLICY

Joseph F. Lovett
MEDIA

The George Gund Foundation
COMMUNITY SERVICE

Hydeia L. Broadbent
THE PEDRO ZAMORA MEMORIAL AWARD FOR YOUTH ADVOCACY

Timothy A. Boggs
FOR EXEMPLARY SERVICE TO AIDS ACTION

Wednesday, April 9, 1997

The Lansburgh Theatre

450 Seventh Street, NW
Washington, DC

Major Sponsor
Time Warner Inc.

Sponsors

American Airlines
David Geffen
GlaxoWellcome
Thomas Healy and Fred P. Hochberg
Merck & Co., Inc.
Microsoft
Craig R. Miller
Miller, Zeichik and Associates, Inc.
Ogilvy Adams & Rinehart
Pfizer, Inc.
Roche Laboratories, Inc.

Reception 6:30 p.m.

Awards Ceremony 7:30 p.m.

Buffet Supper 8:30 p.m.

In-building parking available

AIDS Action National Leadership Awards

D.C. Advocates

Andrew E. Barrer and Peter H. Ballinger
Mike Bento
Michael and Carol Berman
Timothy A. Boggs and James Schwartz
Stephen A. Bouchard
Daniel T. Bross and Robert S. Cundall
Charles Francis and Walter Nichols
Steve Glassman
John F. Guerra and Jay Coburn
Bill Hopkins and Joe Gale
Robert Kabel
R.O. Lehmann
Nancy R. Levenson
Paul P. Massa and Brian Tinkham
Thomas McCusker
Dan Melman and Ed Rogers
Fred Miller and Brian Manuel
Aubrey L. Sarvis
John Schappi
Jan Schoonmaker
Rick Scobey and Bruce Ragsdale
Michael Shelton
Jaen Whitehead
Peters D. Willson
Christopher Wolf

Executive Host Committee

American Psychological Association
Beverly F. Baker, *The Mautner Project*
Mark Barnes and John Grimaldi, M.D.
Andrew E. Barrer and Peter H. Ballinger
Mike Bento
Elizabeth Birch, *Human Rights Campaign*
Timothy A. Boggs and James Schwartz
Daniel T. Bross and Robert S. Cundall
Wes Combs and Greg Albright
Jim Graham, *Whitman-Walker Clinic*
David C. Harvey, *AIDS Policy Center for Children, Youth and Families*
Bill Hopkins and Joe Gale
Mike Isbell, *Gay Men's Health Crisis*
Richard Jacobs and David Church
David Johnson and Pat Griffin
Robert Kabel
Paul Kawata, *National Minority AIDS Council*
Nancy R. Levenson
James Loyce, Jr., *AIDS Project Los Angeles*
Paul P. Massa and Brian Tinkham
NYNEX
Victoria L. Sharp, M.D.
Chuck Supple
Anthony E. Varona
David D. Wexler
Bob Witeck and Bob Connelly

Host Committee

Greg R. Adams
Mickie Ballotta, *Food & Friends*
Vic Basile
Brian K. Bond, *Victory Fund*
Daniel Brenner
Jerry N. Clark
Warren Coats, M.D.
Brian Johnson
Fred Miller and Brian Manuel
Mr. and Mrs. Carl H. Oppenheim
Martin Ornelas-Quintero, *National Latina Lesbian & Gay Organization*
Helen Schietinger
Carl Schmid
Ed Senn
Jane Silver, *AmFAR*
Winnie Stachelberg
Dace Stone
Terry Stone, *Northwest AIDS Foundation*

Committees in formation



AIDS ACTION FOUNDATION

AIDS Action Foundation • 1875 Connecticut Avenue, NW, Suite 700 • Washington, DC 20009

Thank you for your support of AIDS Action.

To learn more about the work of AIDS Action, please contact the Development Office by calling (202) 986-1300 x 3044.

Foundation Co-Chairs

Daniel T. Bross Paul R. Massa

Daniel Zingale, Executive Director

AIDS Action Foundation is a 501(c)(3) organization fighting the AIDS epidemic by working for public policies that help prevent new infections, care for people already infected, and search aggressively for a cure. AIDS Action Foundation works in partnership with AIDS Action Council, representing more than 1,400 community-based AIDS organizations and the individuals they serve.



national leadership awards

Office of
National AIDS Policy

Correspondence Routing Slip

FILE COPY

Tracking Number: 93614

Date Rcvd: 03-25-97

From: Mathilde Kumi, Ph.D. - AMFAR

Letter address to Hillary Rodham Clinton

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

I will bring up in DPC
1 copy - Tues.

To Support Staff: _____

Date of Response: Copy taken to DPC mtg 4/1/97 by Eric

n:\corresli



AmFAR

733 THIRD AVENUE
NEW YORK, NY 10017-3204
TEL (212) 682-7440
FAX (212) 682-9812

BOARD OF DIRECTORS

Founding National Chairman
Elizabeth Taylor

*Founding Co-Chair and
Chairman of the Board*
Mathilde Krim, Ph.D.

Vice-Chairman of the Board
Thomas B. Stoddard, Esq.

President
Mervyn F. Silverman, M.D., M.P.H.

Treasurer
Wallace Sheft, C.P.A.

Secretary
The Rt. Rev. William E. Swing

Directors
Arlen H. Andelson, Esq.
Zev Braun
John Breglio, Esq.
Robert L. Burkett, Esq.
Jonathan Canno
Kenneth Cole
Wafaa El-Sadr, M.D., M.P.H.
Mrs. Michael D. Eisner
Harvey V. Fineberg, M.D., Ph.D.
Michael Fuchs
Jerome E. Groopman, M.D.
Beatrice A. Hamburg, M.D.
James C. Hormel, Esq.
Arnold Klein, M.D.
Michael J. Klingensmith
Jay A. Levy, M.D.
Maurice Marciano
Kenneth H. Mayer, M.D.
Mrs. Maxine Mesinger
Douglas P. Morris
Lincoln E. Moses, Ph.D.
Declan Murphy
Jane F. Nathanson
The Rev. Dr. Randolph Nugent
Leonard Rabinowitz
Michael D. Shriver
Peter R. Staley
Michael Ward Stout, Esq.

Directors Emeriti
Arthur J. Ammann, M.D.
Jonathan M. Mann, M.D., M.P.H.
Abigail Van Buren
Joel D. Weisman, D.O.

In Memoriam
Sheldon W. Anderson
Mrs. Albert D. Lasker
Peter Scott, Esq.

OFFICES

Los Angeles
5900 Wilshire Boulevard
Los Angeles, CA 90036-5032
Tel (213) 857-5900
Fax (213) 857-5920

Public Policy
1828 L Street, N.W., Suite 802
Washington, DC 20036-5104
Tel (202) 331-8600
Fax (202) 331-8606

March 13, 1997

Mrs. Hillary Rodham Clinton
Office of the First Lady, West Wing
The White House
Washington, DC 20500

Dear Mrs. Clinton,

An international conference entitled "Global Strategies for the Prevention of HIV Transmission from Mothers to Infants" will be held in Washington, D.C., from September 3 to September 6, 1997.

As Chairman of the Board of one sponsoring organization, but on behalf of all, I write to extend to you a most cordial invitation to join us on the opening day of this important conference and to ask you to deliver the keynote address.

The conference will bring together leading scientists, physicians and public health officials from around the world for the purpose of devising strategies to achieve a global reduction in the perinatal transmission of HIV.

I know that this issue is close to your heart. I remember the gathering you hosted and the moving address you delivered at the White House, on May 22, 1995. That event launched an educational advertising campaign, created by the Pediatric AIDS Foundation (PAF) and the Advertising Council, to alert American women to the possibility of reducing mother-to-infant HIV transmission. The number of infants diagnosed with HIV/AIDS in the United States in 1996 was half of what it had been in previous years. This reduction has unfortunately not occurred in other nations, particularly developing ones, where the number of children born with HIV ominously continues to rise. (This tragic reality may become vividly apparent to you during your upcoming trip to Africa.) The goal of the upcoming conference is the identification of effective educational and therapeutic interventions that can be used by all nations to reduce the rate of mother-to-infant HIV transmission.

In addition to the humanitarian merit of its purpose, the conference has two aspects deserving mention:

Mrs. Clinton
March 13, 1997

Page 2.

First, this conference attests to the existence of a strong partnership between the public and private sectors: it is sponsored by the American Society of Microbiology and the Office of AIDS Research at the National Institutes of Health (NIH). Co-sponsors are the Centers for Disease Control and Prevention, the NIH's Fogarty International Center, the NIH's National Institute of Allergy and Infectious Diseases, and the NIH's National Institute of Child Health and Human Development from the public sector; and from the private sector, the International AIDS Society and the American Foundation for AIDS Research (AmFAR).

Secondly, the research effort, both basic and clinical, that led to the finding that antiviral therapy given to HIV-infected women during pregnancy can protect their newborns, was done entirely in this country, with both private (AmFAR and PAF) and public support (NIH). The planned conference will be an opportunity to position the U.S. as the country that has not only carried out the research but also assumed leadership in applying research findings to the task of sparing millions of children's lives throughout the world.


Dr. Arthur Ammann, a renowned pediatric immunologist, who was formerly PAF's Director of Research and is now the President of AmFAR, spearheaded the organization of this conference and will be its Chairman. Dr. Ammann's Curriculum Vitae and a preliminary conference program and budget are enclosed. The budget reflects broad support for the conference from the pharmaceutical industry.

Should you or your office have any questions or need any additional information, please feel free to contact Dr. Ammann or me directly. I can be reached at 212-988-7655; Dr. Ammann, at 415-451-1814.

It is our fervent hope that you will accept our invitation. Your participation would greatly add to the prestige of a conference of historic importance and would help spread its life-saving message throughout the world.

With warm personal regards, I remain,

Respectfully yours,


Mathilde Krim, Ph.D.
Founding Co-Chair and
Chairman of the Board

FYI

ARTHUR J. AMMANN
104 Dominican Drive
San Rafael, CA 94901

Hillary Clinton gets look at Zimbabwe 'baby dumping'

Associated Press

HARARE, Zimbabwe — Eviated by her mother, spurned by her boyfriend, desperately afraid, the girl crouches in the bush, gives birth in silence, then walks away from her baby.

A village "auntie" finds the baby, confronts the girl and helps smooth things over with her mother to let her return home.

"Baby dumping," demonstrated for first lady Hillary Rodham Clinton in a skit yesterday by teen-age girls at a family-planning clinic, causes great anxiety in Zimbabwe.

Clinics like Kuwadzana Poly-clinic, where the American VIP watched the teens' presentation, are trying to combat unwanted pregnancies that lead young mothers to leave babies to die.

They have lowered Zimbabwe's birth rate but still confront daunting challenges of "AIDS orphans"

and the spread of sexually transmitted diseases.

With the help of U.S. aid money, the Kuwadzana is trying to reduce the transmission of HIV by dispensing condoms, is treating sexually transmitted diseases and is counseling men and women on ways to avoid pregnancy.

It is the type of foreign aid that deserves to remain intact, Clinton said — especially since such efforts cost so little. U.S. aid to all countries comprises about 1 percent of the total federal budget, she said.

"There are a lot of misconceptions in our country about foreign aid," the first lady said. "One of my hopes is through visits like this, where you can see people on the front lines working to use the money which the United States has provided ... more Americans would be proud."

Clinton and daughter Chelsea are halfway through a two-week visit to Africa.

Independent J. 3/23/97

A Conference on
Global Strategies
for the Prevention
of HIV Transmission
From Mothers
to Infants

September 3-6, 1997
Washington, DC



A Conference on Global Strategies for the Prevention of HIV Transmission From Mothers to Infants

September 3-6, 1997

Washington, DC

Meeting Location:

Hyatt Regency Crystal City

Announcement, Registration, and
Call for Abstracts

Contents

Meeting Sponsors and Cosponsors

Page 4

Organizing Committee Members

Page 5

General Information

Page 6

Calendar of Important Dates

Page 7

Agenda at a Glance

Page 8

Full Meeting Agenda

Page 9

General Registration and Scholarship
Information

Page 15

Hotel Reservations

Page 16

Abstract Submission Guidelines

Page 17

Contacts for Additional Information

Page 18



Meeting Sponsors and Cosponsors

- Sponsored by the American Society for Microbiology
- In collaboration with the Office of AIDS Research, National Institutes of Health (NIH)

Cosponsored by:

- American Foundation for AIDS Research (AmFAR)
- Centers for Disease Control and Prevention (CDC)
- Fogarty International Center, National Institute of Allergy and Infectious Diseases, and National Institute of Child Health and Human Development, NIH
- International AIDS Society (IAS)



Organizing Committee Members

Meeting Chair: Arthur J. Ammann, M.D.
American Foundation for AIDS Research (AmFAR), USA

Vice Chairs: Patricia E. Fast, M.D., Ph.D.
National Institute of Allergy and Infectious Diseases, NIH, USA

Mark Feinberg, M.D., Ph.D.
Office of AIDS Research, NIH, USA

Peter Piot, M.D.
Joint United Nations Programme on HIV/AIDS, Switzerland

Sumner J. Yaffe, M.D.
National Institute of Child Health and Human Development, NIH, USA

Committee Members:

Georgette Adjorlolo, M.D., Ivory Coast
Kenneth Bridbord, M.D., USA
Sergio Augusto Cabral, M.D., Brazil
Cipriano Canosa, M.D., Spain
Mary Glenn Fowler, M.D., M.P.H., USA
Gerald Friedland, M.D., USA
Jonathan Mann, M.D., M.P.H., USA
Richard Marlink, M.D., USA
Francis A. Mmiro, M.B.Ch.B., FRCOG, Uganda
Lynne Mofenson, M.D., USA
Catherine Peckham, Ph.D., UK
Mrudel A. Phadke, M.D., India
Martha F. Rogers, M.D., USA
Paolo Rossi, M.D., Italy
Christine Rouzioux, M.D., France
William T. Shearer, M.D., USA
Patricia Uribe-Zuñiga, M.D., Mexico
Mark A. Wainberg, Ph.D., Canada
Catherine M. Wilfert, M.D., USA



General Information

Advances in therapy to prevent HIV transmission from mothers to infants have brought hope to thousands, but transmission of HIV continues to increase in developing countries. To reduce HIV transmission worldwide, it is imperative that we identify effective intervention strategies that can be used by all nations to reduce maternal-to-infant HIV transmission. This international conference seeks to address critical issues by combining multidisciplinary scientific updates with topic-specific workshop presentations. Specific goals of the conference are to provide:

- ▶ Updates on current research and concepts concerning prevention of maternal-to-infant HIV transmission.
- ▶ Opportunities for researchers and public health workers from developing countries to identify implementation obstacles, practical applications of current research and clinical results, and ways to further extend knowledge to reduce maternal-to-infant HIV transmission.

The meeting will consist of:

- ▶ Presentations over two and one-half days of the most recent scientific information relating to HIV transmission and detailed expert sessions on issues of the highest priority for developing economical and effective intervention strategies. Abstract and poster sessions will provide opportunities for individual and group discussions of important international studies.
- ▶ Workshops conducted over an additional one and one-half days. Attendance will be limited to 50 people per session. The workshops will provide interactive instruction for applying newly discovered information that affects mother-to-infant HIV transmission. Participants will receive written syllabi that can be used as "how to" documents to implement intervention strategies.

Calendar of Important Dates

May 15, 1997

Abstract submission deadline for consideration of poster presentation

July 1, 1997

Abstract submission deadline for inclusion in abstract book

July 3, 1997

Early registration deadline

August 2, 1997

Deadline for cancellation of registration
(with full refund less \$50 fee)

August 12, 1997

Hotel room reservation cutoff

(to be provided by Bridbord)

Deadline for scholarship applications

August 15, 1997

Deadline for late-breaking abstracts
(will not be included in the abstract book)

August 25, 1997

Registration deadline

(onsite registration will be available after this date as
space allows)



Please peel off this
sticker and place it
on your calendar.

Agenda at a Glance

Thursday, September 4, 1997	
10:00-12:00	• REGISTRATION

Friday, September 5, 1997	
SCIENTIFIC SESSIONS	EXPERT SESSION
10:00-12:00 • REGISTRATION • Worldwide Epidemiology and Risk Factors • Current Therapeutic Strategies for the Prevention of HIV Transmission From Mothers to Infants • Primary Prevention of Infection in Women • Peripartum Treatment Issues Affecting HIV Transmission From Mothers to Infants	10:00-12:00 • Current Technology for the Diagnosis of HIV Infection in Infants

Friday, September 5, 1997	
SCIENTIFIC SESSIONS	EXPERT SESSION
10:00-12:00 • Viral Correlates of Perinatal HIV Transmission • Immunologic Correlates of Perinatal HIV Transmission • Viral and Host Genetics of HIV Transmission	10:00-12:00 • Therapeutic Rationale for Preventive Strategies: New Therapies and Future Priorities

Friday, September 5, 1997	
SCIENTIFIC SESSIONS	EXPERT SESSION
10:00-12:00 • Active and Passive Immunotherapy for Prevention of HIV Transmission From Mothers to Infants • Emerging Treatment and Animal Models for Designing Strategies for Prevention of HIV Transmission From Mothers to Infants • WORKSHOPS	10:00-12:00 • Current Therapeutic Debate: What To Use, When To Start, When To Change, When To Stop

Saturday, September 6, 1997	
10:00-12:00	• WORKSHOPS (to be repeated)

Full Meeting Agenda

Wednesday, September 3, 1997

SCIENTIFIC SESSIONS

Morning Sessions

Worldwide Epidemiology and Risk Factors

Global Perspective of HIV Transmission and Risk Factors

Awa Coll-Seck, M.D.

Joint United Nations Programme on HIV/AIDS, Switzerland

Epidemiology and Risk Factors of HIV Transmission in the United States

Martha F. Rogers, M.D.

Centers for Disease Control and Prevention, USA

Epidemiology and Risk Factors of HIV Transmission in Europe

Catherine Peckham, Ph.D.

Institute of Child Health, UK

Current Therapeutic Strategies for the Prevention of HIV Transmission From Mothers to Infants

Setting Worldwide Goals for Reducing Transmission From Mothers to Infants

Arthur J. Ammann, M.D.

American Foundation for AIDS Research, USA

Timing of HIV Transmission

Marie-Louise Newell, Ph.D., UK

Intervention Strategies for Reducing Transmission

Lynne Mofenson, M.D.

National Institute of Child Health and Human Development, NIH, USA

Implementation of Therapy To Reduce Transmission

Christine Rouzioux, M.D.

Hôpital Necker-Enfants Malades, FR

Late-breaking Results: Clinical Trials To Reduce Transmission

Afternoon Sessions: **Primary Prevention of Infection in Women**

Impact of Treatment of Sexually Transmitted Diseases

Maria Wawer, M.D.

Columbia University School of Public Health, USA

Ronald H. Gray, M.D.

Johns Hopkins University School of Hygiene and Public Health, USA

Impact of Treatment Using Microbicides for Sexually Transmitted Diseases

Zeda Rosenberg, Ph.D.

National Institute of Allergy and Infectious Diseases, NIH, USA

Evaluation and Future Direction of Vaginal Cleansing To Reduce HIV Transmission

Cultural Issues Affecting HIV Transmission From Mothers to Infants

Late-breaking Results

Peripartum Treatment Issues Affecting HIV Transmission From Mothers to Infants

Antiretroviral Therapy During Pregnancy

Howard Minkoff, M.D.

SUNY Health Science Center, USA

Caesarian Section and Prolonged Rupture of Membranes

Laurent Mandelbrot, M.D.

Maternité Port Royal, FR

Impact of Nutritional Interventions

Richard D. Semba, M.D., M.P.H.

Johns Hopkins University School of Medicine, USA

Current Status of Breast-feeding Studies on Preventing HIV Transmission

Joan Kriess, M.D.

University of Washington, USA

The Placenta as a Barrier or Facilitator of HIV Transmission

David A. Schwartz, M.D.

Grady Memorial Hospital, USA

Edwina Popek, D.O.

Baylor College of Medicine, USA

Late-breaking Results

EXPERT SESSION

Evening Session: Current Technology for the Diagnosis of HIV Infection in Infants
Seuleyman Mboup, Pharm.D., Ph.D.
University Cheikh Anta Diop, Senegal

James Mullins, Ph.D.
University of Washington, USA

Thursday, September 4, 1997

SCIENTIFIC SESSIONS

Morning Session: **Viral Correlates of Perinatal HIV Transmission**

Relevance of Viral Load in the Pathogenesis of HIV Infection
David Ho, M.D.
Aaron Diamond AIDS Research Center, USA

Maternal Viral Load and HIV Transmission
J. Brooks Jackson, M.D.
Johns Hopkins Medical Institute, USA

Late-breaking Results

Immunologic Correlates of Perinatal HIV Transmission

Cellular Immune Responses and HIV Transmission
Katherine Luzuriaga, M.D.
University of Massachusetts Medical School, USA

HIV-Specific Antibody Responses and HIV Transmission
John P. Moore, Ph.D.
Aaron Diamond AIDS Research Center, USA

The HIV-Exposed and Uninfected Population
Sarah L. Rowland-Jones, D.M., M.R.C.P.
Institute of Molecular Medicine, UK

Late-breaking Results



Afternoon Session: Viral and Host Genetics of HIV Transmission

Viral Genetics of Mother-to-Infant HIV Transmission---Global Perspective
Bette Korber, M.D., Ph.D.
Los Alamos National Laboratory, USA

Genetics of Host Resistance to HIV Transmission---U.S. Studies
Richard A. Koup, M.D.
University of Texas Southwest Medical Center, USA

Genetics of Host Resistance to HIV Transmission in the International Setting
Frances Gotch, Ph.D.
Chelsea & Winchester Hospital, UK

Late-breaking Results

EXPERT SESSION

**Evening Session: Therapeutic Rationale for Preventive Strategies:
New Therapies and Future Priorities**

Cipriano Canosa, M.D.
Hospital "Casa de Salud," Spain

Susie Andries Nogueira, M.D.
Universidade Federal de Rio de Janeiro, Brazil

Mary Glenn Fowler, M.D., M.P.H.
National Institute of Allergy and Infectious Diseases, NIH, USA

Lynne Mofenson, M.D.
National Institute of Child Health and Human Development, NIH, USA

Friday, September 5, 1997

SCIENTIFIC SESSIONS

**Morning Session: Active and Passive Immunotherapy for Prevention of HIV
Transmission From Mothers to Infants**

Vaccines: What Are the Next Steps?
Patricia E. Fast, M.D., Ph.D.
National Institute of Allergy and Infectious Diseases, NIH, USA

Passive Antibody Trials: Roles as Therapeutic Agents in the International Setting

Late-breaking Results

**Emerging Treatment and Animal Models for Designing Strategies
for Prevention of HIV Transmission From Mothers to Infants**

Recent Developments in Making Passive Antibody Therapy a Reality

Nancy L. Haigwood, Ph.D.

University of Washington, USA

Using Animal Models To Design Prevention Strategies

Marta L. Marthas, Ph.D.

California Regional Primate Research Center, University of California at Davis, USA

New Therapies: What's in It for the International Community?

Mark A. Wainberg, Ph.D.

Jewish General Hospital, Canada

Late-breaking Results

Afternoon Session:

Workshops

Design and Implementation of Clinical Studies in the International Setting

Facilitating Laboratory Studies in the International Setting

Nutritional Intervention

Drug Accessibility and Availability in the International Setting

Developing Programs for Addressing Family and Community Issues

Nursing and Midwifery in the International Setting

Political, Ethical, Legal, and Human Rights Issues: Confronting Implementation
of Global Strategy

Tools for Education and Communication in the International Setting

Implementation of HIV Counseling and Testing in the International Setting

Update on International Trials To Prevent HIV Transmission From
Mothers-to-Infants

EXPERT SESSION

Evening Session:

Current Therapeutic Debate: What To Use, When To Start, When To Change, When To Stop?

Stephane Blanche, M.D.
Hôpital Necker-Enfants Malades, FR

Laurent Mandelbrot, M.D.
Maternité Port Royal, FR

Yvonne J. Bryson, M.D.
University of California, Los Angeles Medical Center, USA

Katherine Luzuriaga, M.D.
University of Massachusetts Medical School, USA

Saturday, September 6, 1997

Morning Session:

Workshops To Be Repeated



General Registration and Scholarship Information

Registration Fee and Attendance Limitations and Cancellation Policy

To register for the meeting, please complete the enclosed registration form and return it by mail or fax. You may also register online at [HTTP://MEETINGS.S-3.COM/HIV](http://MEETINGS.S-3.COM/HIV). You may include a check to cover your registration fee, or send a check at a later date. Please note: Your check must be received on or before July 3, 1997, for you to qualify for the early registration fee of \$225. After July 3, the registration fee is \$275. A student fee of \$150 is available to those with proof of full-time enrollment at a degree-granting university or college.

The registration fee will allow you access to the scientific, expert, and poster sessions; any late-breaking sessions; and all coffee breaks. You will receive program and abstract books at the meeting.

For an additional fee of \$35, you may attend up to six workshops and receive workshop syllabi for each workshop you attend. Workshops are approximately 2 hours in length. To facilitate discussions, we are limiting participation to 50 attendees per workshop. Please indicate your first and second choices for up to six workshops on the enclosed registration form. The meeting organizers will make every attempt to repeat the most popular workshops; however, because space is limited, it may not be possible to accommodate all choices. If there is a greater interest in a workshop than space available, assignments will be determined based on the order that the registrations are received. Additional syllabi for workshops you were unable to attend will be available for purchase at the meeting. We urge all participants to register as early as possible.

If workshops are filled prior to the meeting, onsite registration will be limited to the scientific, expert, and poster sessions only.

Cancellation Policy

Refunds (less a \$50 administration fee) will be issued for written cancellations received prior to August 6, 1997, at 5:00 p.m. Eastern Time. No refunds for cancellations will be accepted after August 6, 1997. No telephone cancellations will be accepted. Please submit cancellation letters to Mr. Alfred Nimocks at the address or fax number listed on the registration form. All refunds will be issued after the meeting.

Scholarship Program

A limited number of scholarships will be available to persons living with HIV/AIDS as well as highly qualified persons from developing countries and newly independent states. The scholarships will cover the conference registration fee, travel to the Washington, DC, area, hotel accommodations

while attending the conference, and meals and incidental expenses. Funding priority will be given to individuals whose abstracts were submitted and accepted, to persons whose participation at this meeting will clearly enhance their work in their own country or community, and to persons who will have the opportunity to share the skills and knowledge they receive at the meeting. Please indicate your request for a scholarship application packet on the enclosed registration form.

Media Registration

Proof of accreditation is required for media registration. Please send a photocopy of your press credentials or a letter verifying your assignment to this meeting on the stationery of your media organization to Mr. Alfred Nimocks at the address or fax number listed under "Contacts for Additional Information" (page 18). Media registration is limited. Your registration will be confirmed following approval from the meeting organizers.

Confirmation Letter and Logistical Information

Upon receipt of your registration, you will receive a confirmation letter and additional logistical information. Also enclosed will be a receipt for your paid conference fee or an invoice if you have not paid yet.



Hotel Reservations

All sessions will be held at the *Hyatt Regency Crystal City*, 2799 Jefferson Davis Highway, Arlington, VA 22202. A limited block of rooms has been reserved at the Hyatt Regency Crystal City for check in on Tuesday, September 2, and check out on Saturday, September 6, at the reduced meeting rate of \$130.60 per night, inclusive of tax. The block of rooms will be held until August 12, 1997. Please call the hotel directly at (703) 418-1234 to make your reservation. To receive the reduced rate, you must reference the *Global Strategies for Prevention of HIV Transmission From Mothers to Infants* conference when making your reservation. After August 12, 1997, reservations will be accepted at the Hyatt Regency Crystal City on a rate- and space-available basis. If the hotel rooms reserved in the meeting room block sell out, the hotel staff will refer you to other area hotels.

Arlington, Virginia, is a suburb of Washington, DC, and is served by Washington National and Dulles International Airports - as well as by Amtrak to Union Station.



Abstract Submission Guidelines

The abstract submission deadline for consideration in the poster session is May 15, 1997. Please note that fax copies will not be accepted. Abstracts received after May 15 and prior to July 1 will be included in the abstract book; however, they will **not be** considered for poster presentations. Abstracts concerning late-breaking research may be submitted after July 1 for distribution during the meeting. Abstract guidelines and two abstract submission forms (a standard form and a blinded form) are included in the back pocket of this booklet. Abstracts may be submitted for one of the following topic areas:

- Worldwide Epidemiology and Risk Factors
- Antiretroviral Therapeutic Strategies and Outcomes for Preventing HIV Transmission From Mothers to Infants
- HIV Counseling, Testing, and Diagnosis
- Primary Prevention of Infection in Women
- Peripartum Treatment Issues for the Prevention of HIV Transmission From Mothers to Infants
- Viral Correlates of Perinatal HIV Transmission
- Immunologic Correlates of Perinatal HIV Transmission
- Viral Genetics and HIV Transmission
- Host Genetics and HIV Transmission
- Active Immunization for the Prevention of HIV Transmission
- Passive Immunization for the Prevention of HIV Transmission
- New Therapies for the Prevention of HIV Transmission
- Animal Models for the Evaluation of HIV Transmission
- Family and Community Issues in HIV Transmission
- Political, Ethical, and Human Rights Issues
- Education and Communication



Contacts for Additional Information

Logistical Matters

Mr. Alfred Nimocks

Social & Scientific Systems, Inc.

(Support contractor to the Office of AIDS Research, NIH)

7101 Wisconsin Avenue

Suite 1300

Bethesda, MD 20814-4805

USA

(800) 749-9620 (for U.S. callers only)

(301) 986-1216 (for calls from outside the U.S., call collect between

9 a.m. and 5 p.m. Eastern Time)

(301) 913-0351 (fax)

an@s-3.com (e-mail)

Scientific Program Information

Arthur Ammann, M.D.

104 Dominican Drive

San Rafael, CA 94901

USA

(415) 451-1814 (telephone)

(415) 456-2622 (fax)

Ammannndoc@aol.com (e-mail)

List of Inserts:

Registration Form

Abstract Preparation and
Submission Guidelines

Abstract Submission
Form

Blinded Abstract
Submission Form

Sample Abstract
Submission Form

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: 63615

Date Rcvd: 03-25-97

From: Theresa McGovern
The HIV Law Project

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

Write a cover letter to
Shirley T. C. to Glen
Henderson Asking for an
Appt.

To Support Staff: _____

Date of Response: 4/4/97


*Send a copy of meeting etc
that Ser. should see her.*

n:\corresli

THE WHITE HOUSE
WASHINGTON

APR - 4 1997

The Honorable Donna Shalala
Secretary
Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, DC 20201


Dear Secretary Shalala:

I am forwarding a copy of a letter I received from Theresa McGovern, Legal Director, The HIV Law Project, New York City, requesting an appointment with you. She is a leader in advocacy of women's issues on the Hill for over a decade.

I am recommending that you meet with Ms. McGovern.

Sincerely,



Eric P. Goosby, MD
Acting Director
National AIDS Policy Office

Enclosure

cc: Glen Harrelson, HHS

FAX COVER SHEET

**The HIV Law Project
841 Broadway, Suite 608
New York, NY 10003
Phone: (212) 674-7590
Fax: (212) 674-7450**

**TO: Dr. ERIC GOOSBY
FAX: (202) 632-1096**

FROM: Theresa McGovern

3 PAGES TOTAL, INCLUDING FAX COVER SHEET

Enclosed is a copy of a letter sent via regular mail.

I hope to hear from you soon.

--Theresa McGovern

Please contact (212) 674-7590 if you have any questions regarding this fax

HIV

Theresa M. McGovern, Esq., Co-Executive Director

Bebe J. Anderson, Esq., Co-Executive Director

Carol M. Suzuki, Esq.

Victoria F. Neilson, Esq.

Gretchen Morales, Esq.

March 24, 1997

Dr. Eric Goosby
Acting Director
Office of National AIDS Policy
750 17th Street, NW
Suite 600
Washington DC 20503

Dear Dr. Goosby,

I am writing to renew my request for a meeting with the Secretary to discuss any plans to fund and/or unblind the CDC's newborn seroprevalence study of childbearing women.

As you may know, the New York State Legislature awarded the HIV Law Project funds to administer a Newborn Testing Hotline. The Hotline is designed to respond to anyone who has questions, problems or concerns as a result of the State's implementation of the new mandatory newborn HIV testing program. Although the New York State Department of Health blocked the issuance of the funds for the hotline and refused to publicize the "800" number in state-funded facilities, we have nonetheless received some disturbing information, including reports of:


- Hospital personnel threatening to report women to the child welfare authorities if they refuse either to take AZT or consent to AZT administration to their infant. Most women are so afraid of a charge of medical neglect that they acquiesce.
- Newborns' positive test results being sent to the wrong hospital, resulting in repeated confidentiality violations of the mother and newborn.
- Regulated prenatal medical providers inadequately or completely failing to offer HIV testing and counseling.

- Women leaving the hospital without being told that their newborns were tested and what a positive result will mean; HIV counselors work only nine to five weekdays, and women who deliver over the weekend check out before counselors can see them.
- Because of a lack of interpreters, women's partners or other relatives serving as translators and withholding information, including an HIV positive test result, from the women.
- Inadequate and/or inaccurate information being given to women who test positive.
- Either a complete lack of follow up after a woman receives a certified letter asking her to return and she does not, or aggressive, inappropriate follow up, such as standing by a mother's doorway, etc.
- No guarantee of healthcare for women and children newly identified as HIV-positive.
- A woman's partner beating her up in the hospital after he was informed of her HIV status.

All of these reports violate the stated objectives of mandatory newborn testing and evidence a disturbing disregard for affected families. They further underscore the purely cosmetic value of unblinding the newborn seroprevalence study. Please urge the Secretary to meet with us to discuss these matters as soon as possible.

Thank you for your assistance.

Sincerely,



Theresa McGovern
Legal Director

FILE COPY

Office of
National AIDS Policy

Correspondence Routing Slip

Enc -
URGENT

Tracking Number: G 3611

Date Rcvd: 3/20/97

From: Douglas Sermasek & Walter Weiss
Regenon Pharmaceuticals, Inc.

Staff Action:

Reviewed By Eric: ☒ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____


Recommendations/Instructions:

I will not attend.
Send regrets. T. Ear

To Support Staff: _____

Date of Response: 3-20-97

n:\corresli



**THIS FAX REQUIRES
IMMEDIATE ATTENTION!!**

Date: March 19, 1997

TO: Eric Goosby MD

FAX: (202) 632-1096

FROM: Customer Relations Department

**Medical
Education
Collaborative**

**Number of Pages,
Including Cover Sheet:**

2

**Please call MEC at (800) 442-6632 as
soon as possible if you are interested
in attending this important meeting.**

1800 Jackson Street
Suite 200
Golden, CO 80401
Toll Free: (800) 442-6632
Direct: (303) 278-1900
Fax: (303) 278-1985

MEDICAL EDUCATION COLLABORATIVE
1800 Jackson Street, Suite 200
Golden, CO 80401
(303) 278-1900 - Phone
(303) 278-1985 - Fax

March 19, 1997

Eric Goosby MD
Washington, DC

Dear Dr. Goosby:

On behalf of Agouron Pharmaceuticals, we cordially invite you to attend a **Regional Advisory Panel Meeting**, to be held on Saturday, March 22, 1997 at the Sheraton New York Hotel & Towers in New York, New York.

Based on your knowledge and expertise in Pediatric AIDS, you have been selected to participate with other key opinion leaders to discuss unblinded trial data of VIRACEPT® (nelfinavir mesylate), and to provide recommendations for optimal commercialization and future clinical development of VIRACEPT® in your geographic region.


The agenda for this program is as follows:


10:00 am - 10:30 am	Registration and Coffee
10:30 am - 10:35 am	Welcome - Moderator TBD
10:35 am - 12:00 noon	Scientific Sessions to include Nelfinavir Pivotal Trials, Protease Drug/Drug Interactions, Protease Drug Resistance and Pediatric Clinical Trials
12:00 noon - 12:45 pm	Lunch
12:45 pm - 2:00 pm	Advisory Panel Recommendations on Commercialization and Future Clinical Development of Nelfinavir - Walter Weiss - Agouron Pharmaceuticals
2:00 pm	Adjourn

It is our policy to offer an honorarium of \$1,000.00 for physicians and \$500.00 for advocates and to cover travel expenses. If appropriate for your office, we will follow this policy.

To confirm your attendance to this important meeting, please call Medical Education Collaborative at (800) 442-6632 at your earliest convenience. We hope you can join us in New York on March 22nd!

Sincerely,


Douglas Jermasek
Marketing Manager
Agouron Pharmaceuticals, Inc.


Walter Weiss
Professional Science Liaison
Agouron Pharmaceuticals, Inc.

3/20/97 Spoke w/
Gina -



FILE COPY

Office of
National AIDS Policy

Correspondence Routing Slip

Tracking Number: G3612

Date Rcvd: 03-20-97

From: Greg Ratcliff
GMHC

Staff Action:

Reviewed By Eric: _____ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

Ebenezer Daniels R.Y.I.

To Support Staff: _____

Date of Response: 3-28-97

n:\corresli



March 14, 1997

Eric Goosby, Acting Director
White House Office of AIDS Policy
750 17th Street, NW, Suite 600
Washington, DC 20503

Dear Mr. Goosby:

Gay Men's Health Crisis (GMHC) is currently seeking candidates for the position of Director of Public Policy and Director of Treatment Education and Advocacy. Enclosed you will find position descriptions for each opening.

We would appreciate it if you would share this information with anyone who might want to explore joining the GMHC management team. Our search for qualified candidates is underway and we encourage interested individuals to contact Gregory Ratcliff, Director of Human Resources at (212) 337-3423 or Michael Isbell, Associate Executive Director at (212) 337-3351 for further information.

Thank you for your assistance.

A handwritten signature in black ink that reads "G Ratcliff". The signature is written in a cursive, flowing style.

Greg Ratcliff
Director of Human Resources

We seek to fill the following position:

Director, Public Policy

Administrator of GMHC's public policy and advocacy efforts. Work with the associate executive director in developing strategic public policy advocacy priorities, including local, state and federal relations, communication strategies and agency visibility concerning policy issues. Responsible for agency's grassroots community organizing efforts in accordance with agency's public policy advocacy. Develop and maintain relationships with directors of departments within GMHC and key staff to ensure the public policy advocacy is reflective of the agency.

Reports to: Associate Executive Director.

Qualifications: Extensive understanding of the HIV/AIDS epidemic and related public policies. Excellent writing and communication skills, including public speaking and lobbying experience. Strong understanding of political processes and the effect on public policy. Experience in programmatic development, staff supervision and budget responsibility.

Contact Gregory Ratcliff
Director of Human Resources
129 W. 20th Street
New York, NY 10011-3629
(O) (212) 337-3423
(F) (212) 337-1527
E-mail greg@gmhc.org

GMHC is an equal opportunity employer



Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: G3609

Date Rcvd: 03-12-97

From: Ann Rutherford
American Psychological Association

Staff Action:

Reviewed By Eric: _____ Reviewed By: _____

Assigned To: _____

*Eric: This was referred by
Dr. Pat Hawkins*

RCVD: _____ DONE: _____

Recommendations/Instructions:

Cancelled

To Support Staff: _____

Date of Response: 3-13-97



AMERICAN
PSYCHOLOGICAL
ASSOCIATION

Public Interest Directorate

March 12, 1997

Eric Goosby, MD
Director of HIV/AIDS Policy
Department of Health and Human Services
750 17th Street, NW
Suite 600
Washington, DC 20503

Dear Dr. Goosby:

The Committee on Psychology and AIDS (COPA) is pleased that you are able to join us on Friday, March 14 at 1 p.m. Our meeting will be in the Governor's Suite at the Crystal Gateway Marriott in Arlington, Virginia. I have enclosed a card with directions and telephone numbers for your convenience.

Some of the legislative and policy issues that COPA is concerned about and would like to discuss with you are: needle exchange; behavioral research/interventions to reduce the spread of HIV; behavioral factors in treatment and management of HIV disease; and funding for HIV/AIDS-related mental health services.

I have included an agenda and roster of committee members. We envision this time with you to be informal with an open discussion and exchange of ideas on topics such as those listed above of mutual interest to yourself and COPA. The committee will break for lunch at 12 and if your schedule allows, you are welcome to join us for lunch.

We appreciate your willingness to participate in our meeting. If you have any additional questions, please contact me at 202-336-6052.

Sincerely yours,

Ann Rutherford
Programs Manager
Office on AIDS



AMERICAN
PSYCHOLOGICAL
ASSOCIATION

Committee on Psychology and AIDS

1997

Patricia Hawkins, PhD, Chair

Associate Executive Director
Whitman-Walker Clinic, Inc.
1407 S Street, NW
Washington, DC 20009
(202) 797-3513 W (202) 797-3504 FAX

Nancy Amodei, PhD

The University of Texas
Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX 78284-7818
(210) 567-7400 W (210) 567-7400 FAX
amodei@uthscsa.edu

Peter E. Campos, PhD

Emory University School of Medicine
Clinical and Research Director
Grady Infectious Disease Program
341 Ponce de Leon Avenue
Atlanta, GA 30308
(404) 616-9710 W (404) 616-9700 FAX
pcampos@unix.cc.emory.edu

Alex Carballo-Diéguez, PhD

HIV Center for Clinical & Behavioral Studies
NY State Psychiatric Institute
722 West 168th Street
New York City, NY 10032
(212) 960-2261 W (212) 740-1774 FAX
ac72@columbia.edu

Cynthia A. Gomez, PhD

Center for AIDS Prevention Studies
74 New Montgomery, Suite 600
San Francisco, CA 94105
(415) 597-9267 W (415) 597-9213 FAX
cynthia_gomezpsg@quickmail.ucsf.edu

Jeannette R. Ickovics, PhD

Assistant Professor of Medicine & Psychology
Department of Internal Medicine
School of Medicine
Yale University
IE61 SHM (RWJ Clinical Scholars)
P.O. Box 208025
New Haven, CT 06520-8025
(203) 785-6213 W (203) 785-3461 FAX
ickovic@yalevm.cis.yale.edu

Robert Washington, PhD

St. Francis Center
1377 Rittenhouse Street, NW
Washington, DC 20011
(202) 363-8500 W (202) 333-4540 FAX

APA Staff

John R. Anderson, PhD

Ann Rutherford

Leah Stockett


American Psychological Association
750 First Street, NE
Washington, DC 20002-4242
(202) 336-6042 W (202) 336-6040 FAX

**Preliminary Order of Business
for the
Committee on Psychology and AIDS**

	<u>Agenda Item #</u>
Introduction of COPA Members	1
Review of Fall 1996 Minutes	2
Cross-cutting Agenda Items	3
Review of COPA Activities: Fall 1994 - Present	4
Call for COPA Nominations and Appointment of COPA Chair	5
Office on AIDS Report	6
Protease Inhibitors & Adherence with Clinical Trials	7
Meeting with the Committee on Disability Issues in Psychology	8
HIV/AIDS Advocacy Issues	9
Meeting with Eric Goosby, MD	10
Review of HIV/AIDS Programming for the 1997 & 1998 APA Convention	11
Follow-up to NIH Meetings	12
Next Steps for COPA	13

CRYSTAL GATEWAY Marriott.

1700 Jefferson Davis Highway
Arlington, Virginia 22202
(703) 920-3230
Guest Fax: (703) 271-5212
Sales Fax: (703) 271-5131



Directions

From National Airport: Take U.S. Route 1, follow Crystal City signs exiting airport. Turn left on 20th Street, proceed to South Eads, turn right. Hotel is 1½ blocks on right.

700 Guest Rooms/ 71 Suites/ 10 Parlors

Located on 17 levels, in twin towers, guest rooms feature cable TV, in-room pay movies, telephone with message light, AM/FM alarm clock radio, iron/ironing board. Nonsmoking rooms and accessible rooms available. Concierge Level rooms and Executive Lounge.

Restaurants and Lounges

The *Terrace Restaurant*, overlooking the pool, features casual ambience for breakfast, lunch and dinner. *Tuscany's* serves Northern Italian dinner specialties in an elegant atmosphere; closed on Sundays. The *Atrium Cafe*, ideal for light fare and snacks. *Teams Sports Bar*, casual sports lounge for cocktails and limited menu. Fun atmosphere, authentic sports memorabilia, large-screen TVs (watch as many as 6 different sports events at once), pool tables, video games.

Recreational Facilities

Connecting indoor/outdoor pool. Poolside gym area with aerobic bicycles, Universal® equipment, free weights. Tennis, racquetball and jogging paths nearby.

Places to See/ Things to Do

The Underground Shops, a gallery of 200 specialty shops and eateries—connected to hotel via walkway. Ten minutes from D.C.'s most celebrated attractions of art, history, dining and shopping. Historic Maryland and Virginia sites within 30 minutes' drive. Annapolis and Baltimore, one hour drive.

Shops/ Services

Complimentary airport shuttle to Washington National Airport. Gift shop, valet service, guest laundry, baby-sitting, soda/ice and vending machines, car rental, concierge.

Special Plans

Two for Breakfast™ Weekends.

For details, rates and reservations, call us direct at (703) 920-3230; your travel agent; or the Marriott Reservation Center toll-free in the United States and Canada: 800-228-9290. (Travel agents only call: 800-831-1000.)

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: G3608

Date Rcvd: 03-12-97

From: Elijah E. Cummings
Congress of the U. S. House of Representatives

Staff Action:

Reviewed By Eric: _____ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

See G 3690 & 3601

To Support Staff: _____

Date of Response: 5-2-97

n:\corresli

may 2 '97

ELIJAH E. CUMMINGS
7TH DISTRICT, MARYLAND

COMMITTEE ON
TRANSPORTATION AND
INFRASTRUCTURE

COMMITTEE ON
GOVERNMENT REFORM
AND OVERSIGHT

Congress of the United States
House of Representatives
Washington, DC 20515

2419 RAYBURN BUILDING
WASHINGTON, DC 20515
(202) 225-4741
FAX (202)-225-3178

DISTRICT OFFICE

3000 DRUID PARK DRIVE
BALTIMORE, MD 21215
(410) 367-1900
FAX (410) 367-5331

March 6, 1997

Eric Goosby, M.D.
Acting Director
Office of National AIDS Policy
750 Seventeenth Street, N.W.
Suite 600
Washington, D.C. 20503

Dear Dr. Goosby:


Thank you for agreeing to participate at my annual symposium on HIV/AIDS on May 2, 1997 as the Keynote Speaker.

As indicated in my previous correspondence to you, the focus of the symposium is to disseminate new information on the AIDS issue and offer helpful solutions in terms of education, therapy and continued funding of research to find a cure. I would appreciate it if you speak on current developments as well as existing and future funding programs.

My office will provide you with directions to the Medical School Teaching Facility at the University of Maryland at Baltimore prior to the scheduled symposium. Should you have any questions or require additional information, please feel free to contact Ms. Deborah Perry of my staff at (410) 496-2010.

Again, thank you for agreeing to participate at my HIV/AIDS symposium. I look forward to meeting you on May 2, 1997.

Sincerely,

A handwritten signature in black ink that reads "Elijah E. Cummings". The signature is stylized with a large, sweeping loop at the end of the last name.

Elijah E. Cummings
Member of Congress

EEC/dsp

FILE COPY

Office of
National AIDS Policy

Correspondence Routing Slip

Tracking Number: G3007

Date Rcvd: 03-11-97

From: H. Alexander Robinson
Recreating our Future

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

Recommendations/Instructions:

1/R

To Support Staff: _____

Date of Response: 3-27-97



r e c r e a t i n g o u r f u t u r e

5 March, 1997

Campaign Donors

Eric Goosby, M.D.
Acting Director
National AIDS Policy Office
750 17th Street, NW Suite 600
Washington, DC 20503

visionary lead gift

James C. Hormel

Dear Eric,

foundation gifts

Public Welfare Foundation

Glen Eagles Foundation

The Horizons Foundation

We are writing you today to ask if you would join us as a Sponsor for *Recreating Our Future*, a campaign initiative that will *bring the resources to bear to end the HIV/AIDS epidemic among gay men of color, and cut by 50% the number of new HIV infections by the year 2002*. As a leader in AIDS activism you may already be aware of the following stark statistics:

- Gay and bisexual men of color are the most severely impacted population group within communities of color, accounting for 52% of all total AIDS cases.
- One in every five newly diagnosed clients belongs to a gay and bisexual men of color group.
- Tracking the rates of HIV transmission over a five-year period, the Centers for Disease Control (CDC) reveals: 79% increase for African Americans; 77% increase for Native Americans; 61% increase for Latinos; and 55% Asian/Pacific Islanders.

NTFAP Board of Directors

president
H. Alexander Robinson

vice president
Chris Sandoval

treasurer
Richard Tagle

secretary
Steve Wakefield

directors
Christopher Bates
Esteban Barnaby
Lawrence "Carrie" Farrell
David Herrera
Curtis Harris
Andrew Spieldenner

With a lead gift from James C. Hormel, and support from Public Welfare Foundation, Glen Eagles Foundation and Horizons Foundation, the National Task Force on AIDS Prevention will bring together supporters, donors, and funders to launch *Recreating our Future* in Washington, D.C. A brief summary of the *Recreating Our Future* campaign is enclosed.

We would like to invite you as a Sponsor for the event. The *Recreating Our Future* launch in Washington, DC is scheduled for Thursday, March 27, 1997 from 6 p.m. until 8 p.m. at The Century House, 1309 Rhode Island Avenue, NW (invitation will follow). We request that you contribute or pledge between \$100-\$1000 to the campaign. Your presence and support will inspire others to face our challenges as this epidemic disproportionately impacts gay and bisexual men of color in our country.

AIDS continues to devastate our communities. Research demonstrates that prevention programs slows the spread of HIV. In addition, federal, state and local government are now formulating public health policy that will affect access to new treatments. Therefore, it is imperative for us to heighten our response to the epidemic now.

We hope to count you as one of our supporters who will take a public stand against the further spread of HIV among gay and bisexual men of color. We would appreciate your reply by Friday, March 14. In the meantime, should you have any questions, please do not hesitate to contact Vince Sales, Director of Development, at 415.356.8109.

Campaign Office

National Task Force on
AIDS Prevention
973 Market Street, Suite 600
San Francisco, CA 94103

415.356.8127
fax 415.356.8103
e-mail ntfapdevel@aol.com

Thank you for your thoughtful consideration.

Sincerely,

H. Alexander Robinson
Chair, Host Committee

Can HIV be eradicated?
Dr. David Ho opens Conference
on Retroviruses and OIs.

page 18

Art Market (Street)
Kico Govantes unveils his 'Art
in Transit' along SF artery.

page 16

Working boys
David Arquette and Lukas
Haas are hustlers in 'johns'
see Arts section



BAY AREA REPORTER

Vol. 27 • No. 5 • 30 January 1997

Serving the Gay & Lesbian Community for more than 25 years

Leland House grand opening continues to generate controversy

More resignations, but also public support, in wake of archbishop's letter

by Cynthia Laird

One week before the grand opening of its 45-bed AIDS housing facility in San Francisco, Catholic Charities remains at the center of controversy because of Archbishop William Levada's recent letter to Mayor Willie Brown seeking an exemption from the city's domestic partner benefit law.

The law, which takes effect June 1, requires businesses that contract with the city to provide benefits to domestic partners of employees if they provide those benefits to spouses. Levada contacted Brown December 20 for help in amending the law to exempt contractors that are churches or religiously-affiliated organizations. Otherwise, Levada wrote, the law would require contractors to adopt policies "which would be contrary to the church or organization's religious and

ethical tenets."

There has been no movement by either the Board of Supervisors or the mayor to propose an amendment to the ordinance. Brown has not commented publicly on the controversy, although sources have told the B.A.R. he is furious about the letter.

The timing couldn't have been worse for Levada's actions. It has taken a full seven years for Leland House to open, and by now the public has been invited to attend the facility's grand opening celebration this Thursday, February 6.


Political leaders resign

Since news of Levada's letter was first published in the *Bay Area Reporter* January 9, at least eight people have announced their resignation from the Steering Committee planning the grand opening, and the Honorary Host Committee, made up largely of local community leaders, housing advocates, and health-care professionals.

Earlier this month, two of the three co-chairs organizing the celebration, San Francisco dentist Dr. Rudolf Isch and his partner Ron Hill, resigned in the midst of planning for next week's event. Supervisor Leslie Katz, who co-authored the ordinance, also resigned from the steering committee, writing a strongly worded letter to Bob Nelson, public policy director for Catholic Charities.

"Either Catholic Charities is engaging in religious activities and thus cannot receive city funding," she pointed out, "or is a not-for-profit organization engaging in secular activities that must comply with the law."

Nelson has not commented on the issues



Leland House at 141 Leland Avenue in San Francisco is slated to open next week.

surrounding Levada's letter, citing Catholic Charities policies. However, he did emphasize the need Leland House will help meet in the city.

"The focus needs to be that it's an AIDS housing program we really need, not to let this become a political football. The agenda here is housing for PWAs," Nelson told the B.A.R.

When the first residents move into Leland House in February, according to Nelson, the licensed residential care facility will provide housing and support services such as comprehensive case management, activities and therapeutic recreation, daily living activities, and money management. The facility will be staffed 24 hours a day.

page 26 ▶



How sweet it is: Mr. Mid-Atlantic Leather '97 Mike Siemer of Kansas City, Kan., flashes a victory smile as he embraces his trophy. Siemer won over 10 other contestants at Tracks in Washington, D.C. last Sunday, Jan. 26. For the scoop on the MAL event, see Mister Marcus column on p. 44.

INSIDE

ACT UP	22
BAR Talk	48
Bazaar	44
Classifieds	27
GLAAD	12
Mailstrom	7
Obituaries	24
Open Forum	6
Our Man Friday	9
Out & About	46
Out There	34
Personals	50
Sapphistication	10
Sports Complex	26

NTFAP leaders launch campaign to end AIDS

by Cynthia Laird

Calling it a "revolutionary idea," leaders of the National Task Force on AIDS Prevention (NTFAP) launched an ambitious campaign to end the AIDS epidemic by the year 2002, called "Recreating Our Future," on Thursday, January 23 in San Francisco.

The highlight of the evening was an appearance by NTFAP's founding executive director Reggie Williams, who gave a moving speech about the importance of the campaign to succeed.

The new national campaign was developed in response to the increasing HIV infection rates in people of color communities. Its mission is to "bring the resources to bear to end the AIDS epidemic among gay men of color." The goal is to cut in half the number of new HIV infections among gay men of color and effectively end the epidemic in these communities by 2002.

The campaign involves several compo-

nents, including fundraising, integrating new research into community-based programs, conducting leadership training, conducting research and social marketing campaigns, and promoting public health policies that ensure gay and bisexual men of color are included as a target population for HIV prevention.

Mayor Willie Brown made an appearance to help kick off the fundraising effort and said that if better outreach programs are devised around prevention, perhaps the NTFAP's goal could be met in less than five years.

"It takes a concentrated effort to change that," Brown said.

An estimated 70 people attended the reception, according to Jose Cuellar, NTFAP special events manager.

Intolerable

Williams, who flew in from Amsterdam where he's lived for the past few years, said the NTFAP initiated "Recreating Our Fu-



The sartorially resplendent Reggie Williams (left) with H. Alexander Robinson.

page 27 ▶

FIRST OF TWO SECTIONS

COMMUNITY NEWS

NTFAP

◀ page 1

ture" because members decided they must do something so that the disease doesn't dictate what happens.

"I find it intolerable that this disease has lasted over 15 years. I find it intolerable that young people become infected even before they can drive a car," Williams said.

Gay men of color account for over half the AIDS cases within communities of color; and the HIV infection rates for gay men of color are escalating out of control, he explained.

AIDS, said Williams, "has almost become business as usual," with many people getting "bogged down in the rhetoric."

"We are held captive by our internalized homophobia just as we are put down by other people's racism. There are people dying in the streets outside this very building," he said. "Divas and egos wedge barriers between hopelessness and life. As a person living with this disease, I find that intolerable."

Also appearing at the recep-

tion was James Hormel, openly gay civic leader and multimillionaire heir to the Hormel meatpacking fortune. Hormel was an early supporter of the campaign, and made a very generous financial contribution.

"This is an extremely, extremely important project. Of paramount importance is to save lives," Hormel said. "The goals are commendable."

Chris Sandoval, vice president of the NTFAP board, spoke about the need for the campaign and the importance of "vision," a word people hear over and over when talking about the epidemic.

Harold Rasmussen, from the state Office of AIDS, told the group that "Recreating Our Future" means a great deal to his office.

"This year the state office fought off attacks to take prevention funds. To me, prevention dollars are sacred. We should speak to legislators to give us enough money," Rasmussen said. "This is a time to really, really kick ass with AIDS prevention. Now is the time to step up, not step down."

The president of NTFAP's board, H. Alexander Robinson of

Washington DC, encouraged people to make pledge donations to the campaign. Robinson, a member of the President's Advisory Council on AIDS, said he told fellow members about the campaign and discussed the council taking a position on ending the epidemic.

"That challenge met with a lot of resistance. I said, 'If we're not ending the epidemic, what are we doing?'" Robinson said.

Other board members in attendance were Esteban Barnaby of Oakland, Curtis Harris of New York, Carrie Farrell of Boston, and Christopher Bates of Washington DC. After introducing them, Robinson said that NTFAP is looking to expand the board and diversify it.

"We intend to add some women," he said, which drew a shout of approval from one of the women in the audience. ▼

Contributions to "Recreating Our Future" can be sent to: NTFAP, 973 Market Street, Suite 600, San Francisco, CA 94103. For more information, call NTFAP at (415) 356-8127.

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: G36041

Date Rcvd: 03/07/97

From: Daniel Zingale, Executive
Director of AIDS Action Foundation

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: Canner

RCVD: _____ DONE: _____

Recommendations/Instructions:

see 3621

4/9
Norman OK I will offer

To Support Staff: _____

Date of Response: 4-9-97

n:\corresli Cancelled on Daniel Zingale's voice mail
o

April 9, @ 6:30 P

*on calendar
3/11/97*



March 5, 1997

Mr. Eric Goosby
Acting National AIDS Policy Coordinator
750 17th Street, NW Room 1060
Washington, DC 20503

Dear Mr. Goosby:

On April 9, 1997, AIDS Action Foundation will host the National Leadership Awards program at the Lansburgh Theatre in Washington, D.C. It is our pleasure to invite you to join us for this special evening and be a member of the Honorary Host Committee. As a member of this committee, your name will be listed in the program and promotional materials.

AIDS Action Foundation is a 501(c)(3) organization fighting the AIDS epidemic by working for public policies that help prevent new HIV infections, provide care for people living with HIV and AIDS, and search aggressively for a cure. AIDS Action Foundation works in partnership with AIDS Action Council, representing more than 1,400 community-based AIDS organizations and the people they serve.

The National Leadership Awards are given to those who have shown leadership, commitment, and courage in the battle against AIDS. Awards are presented in six areas. This year's honorees include **Vice President and Mrs. Gore** for Public Service; Associate Director of the Office of Management and Budget, **Nancy-Ann Min** for Public Policy; the amazing young advocate **Hydeia Broadbent** for Advocacy; the creator of ABC's remarkable AIDS awareness specials "In A New Light", **Joseph Lovett** for Media; and **The George Gund Foundation** for Community Service.

Last year approximately 350 people attended the Leadership Awards program and this year we expect an even higher attendance. The evening will begin at 6:30 p.m. with a light hors d'oeuvres reception, followed by an hour-long seated awards presentation, and a spring buffet dinner.

These awards are a tribute to those people who labored professionally and personally in the past year to fight AIDS. We truly hope you will join us in honoring their dedication. A response form is enclosed for your convenience. Please respond by March 14, 1996. Thank you.

Sincerely,

A handwritten signature in black ink that reads "Daniel Zingale". The signature is written in a cursive, flowing style.

Daniel Zingale
Executive Director

1875
Connecticut Ave NW
Suite 700
Washington DC
20009
Fax 202 986 1345
Tel 202 986 1300



dated 3/11/97

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: 63603

Date Rcvd: 03-05-97

From: Salvatore J. Russo / Clifford S. Carter, Jr.
American Bar Association

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: _____

RCVD: _____ DONE: _____

_____ on to do it
on i Camenz + Hellie.

Recommendations/Instructions:

To Support Staff: _____

Date of Response: 4-18-97

n:\corresli

April 18 @ 12 noon

on calendar

ef.



1996-1997

AMERICAN BAR ASSOCIATION

AIDS Coordinating Committee

740 15th Street, N.W.

Washington, D.C. 20005-1009

202/662-1025

FAX: 202/662-1032

Eric Goosby, MD

Acting Director

White House Office of National AIDS Policy

750 17th St., NW

Washington, DC 20503

February 27, 1997

Dear Dr. Goosby:

The American Bar Association (ABA) AIDS Coordinating Committee looks forward to meeting and lunching with you at the Spring meeting of the Committee which will be held, here, at the Washington, D.C., offices of the ABA, on Friday, April 18th at 12:00 p.m. Your own remarks regarding HIV/AIDS policy and the Office of National AIDS Policy followed by discussion of the issues between yourself and committee members should require approximately one hour of your time (longer, of course, if you so desire and your schedule permits).

You may wish to know that, over the course of the weekend meeting, the Committee will be addressing the issue of syringe law/regulations and needle exchange programs. Having said that, the content of your remarks is entirely up to you.

The American Bar Association AIDS Coordinating Committee was created over 9 years ago to be the focal point for the ABA's response to the AIDS crisis. Since that time, the Committee, presently comprised of 22 prominent attorneys from across the nation, has successfully developed programs and championed legal policies which address, in a sensitive, caring and principled way, the legal needs of persons living with HIV and AIDS.

The efforts of the Committee have resulted in, among other accomplishments, the ABA's adoption of an official policy of non-discrimination towards people who are HIV seropositive or who have AIDS. As a result the ABA is able to use its influence to urge that federal, state and local law, and the policies of private entities, conform to the imperative of non-discrimination. More recently, the Committee successfully convinced the ABA House of Delegates to adopt policy related to the regulation, in the best interests of persons with AIDS, of viatical companies, policy regarding standby guardianship of children and advance medical directives, as well as the promotion of model legislation for compassionate release from prisons

CHAIR

Salvatore J. Russo
New York City Health & Hospitals
Corporation
125 Worth Street, Room 527
New York, NY 10013
Tel: 212/788-3300

VICE CHAIR

Robert E. Stern
Blicker & Stern
1919 Pennsylvania Ave., NW, #200
Washington, DC 20006
Tel: 202/457-0753

Section of Administrative Law and Regulatory Practice

COMMITTEE

John Adney

Washington, DC

Section of Taxation

The Honorable Richard T. Andrias
New York, NY

Criminal Justice Section

Harold Datz

Washington, DC

Labor and Employment Law Section

Shelley D. Hayes

Washington, DC

National Bar Association

Michael Isbell

New York, NY

The National Lesbian and Gay Law Association

Steven L. Kessler

New York, NY

New York State Bar Association

Allen W. Kimbrough

Dallas, TX

Consortium on Legal Services and the Public

Helaine Joyce Knickerbocker

New York, NY

Family Law Section

W. Steve Lee

Washington, DC

Section of Dispute Resolution

The Honorable Barbara Levenson

Miami, FL

National Association of Women Judges

The Honorable Edward Terhune Miller

Washington, DC

Judicial Division

Lane Porter, Jr.

Washington, DC

Section of International Law and Practice

Mark E. Rust

Lincolnwood, IL

Tort and Insurance Practice Section

Gabrielle Sigel

Chicago, IL

Litigation Section

Brenda Strama

Houston, TX

Section of State and Local Government Law

Paul Sturgul

Hurley, WI

General Practice, Solo, and Small Firm Section

Allan H. Terl

Fort Lauderdale, FL

Section of Individual Rights and Responsibilities

Rita M. Theisen

Washington, DC

Tort and Insurance Practice Section

Sidney Watson

Macon, GA

Commission on Homelessness and Poverty

STAFF

Penny Wakefield

Section Director

Clifton J. Cortez, Jr.


Project Director


and alternatives to sentencing for non-violent criminal offenders with terminal illnesses.

Your participation at the Spring meeting of the AIDS Coordinating Committee will be extremely beneficial in furthering the dialogue and cooperation previously established between the AIDS legal community and the White House Office of National AIDS Policy.

Thank you for accepting our invitation. We look forward to meeting you.

Sincerely,


Salvatore J. Russo
Chair


Clifton J. Cortez, Jr.
Director

Office of
National AIDS Policy

FILE COPY

Correspondence Routing Slip

Tracking Number: G3601

Date Rcvd: 03-04-97

From: Elijah E. Cummings
Congress of the United States
(House of Representatives)

Staff Action:

Reviewed By Eric: ✓ Reviewed By: _____

Assigned To: CP

RCVD: _____ DONE: _____

Recommendations/Instructions:

See G3690 & 3608

To Support Staff: _____

Date of Response: 5-2-97

n:\corresli

May², 8⁰⁰A

ELIJAH E. CUMMINGS
7TH DISTRICT, MARYLAND

2419 RAYBURN BUILDING
WASHINGTON, DC 20515
(202) 225-4741
FAX (202) 225-3178

COMMITTEE ON
TRANSPORTATION AND
INFRASTRUCTURE

COMMITTEE ON
GOVERNMENT REFORM
AND OVERSIGHT

Congress of the United States
House of Representatives
Washington, DC 20515

DISTRICT OFFICES:

2000 ORLAND PARK DRIVE
BALTIMORE, MD 21215
(410) 387-1900
FAX (410) 387-5331

7900 LIBERTY ROAD
BALTIMORE, MD 21207
(410) 496-2010
FAX (410) 496-2015

754 FREDERICK ROAD
CATONSVILLE, MD 21228
(410) 710-8777
FAX (410) 455-0110

March 3, 1997

Eric Goosby, M.D.
Acting Director
Office of National AIDS Drug Policy
750 Seventeenth St., NW - Suite 600
Washington, D.C. 20503

Dear Dr. Goosby:

I am writing to request that you act as Keynote Speaker for my annual symposium on HIV/AIDS. This symposium is scheduled for Friday, May 2, 1997, in the Medical School Teaching Facility at the University of Maryland at Baltimore, in Baltimore, Maryland.

The audience will be 1) physicians 2) health care professionals 3) municipal, state and federal elected officials and 4) participation from the lay community to include infected individuals. Our focus is to disseminate new information on the AIDS issue and offer helpful solutions in terms of education, therapy and continued funding of research to find a cure.

The symposium will be held from 7:30 a.m. until 2:00 p.m. The Keynote Address will take place at approximately 8:15 a.m. Please know that I believe you have a wealth of knowledge to share with the attendees and would deeply appreciate your participation.

Please send your response to my office at 7900 Liberty Road, Baltimore, MD 21244 or by facsimile to (410) 496-2015. If you or your staff have any questions, please contact Ms. Deborah Perry of my staff at (410) 496-2010.

Sincerely,

Elijah E. Cummings

Elijah E. Cummings
Member of Congress

EEC/vs

Carmen
pls
Schedule
for Eric

EVENT SCHEDULING FORM

Date Received: March 4, 1997

Event Description: Symposium on HIV/AIDS

Location of Event: University of Maryland at Baltimore
Medical School Teaching Facility
7900 Liberty Road, Baltimore

Event Date: May 2, 1997 Time: 8:00 a.m.

Contact Name: Deborah Perry 410/496-2010

Remarks Required: ☒ Yes ☐ No

Length of Remarks: 15 mins. Audience Size: 300

Topic: Current Developments & Funding (see para. 2 of attached ltr.)

Introduction By: Congressman Elijah E. Cummings

Media Coverage: ☒ Yes ☐ No

Questions & Answers: ☒ Yes ☐ No

Referred To:

☐ Eric Goosby ☐ Carmena Parris ☐

☐ ☐ ☐